Marksans Pharma Limited — Updates, 12-08-2025: Press Release

Marksans Pharma reported Q1FY26 revenue of Rs. 620 Cr, up 5% YoY, driven by strong US market growth (+30.6%) from new product launches. Gross profit rose 8.9% with margin expansion, benefiting from easing raw material costs. While EBITDA and net profit were impacted by ramp-up costs, a one-time provision, and forex adjustments, management views these as transient. The company maintains a strong cash balance of Rs. 711 Cr, supporting growth. Integration of the Goa facility is nearing completion, focusing on capacity scaling and efficiency. Demand recovery signs are noted in key markets.